125 related articles for article (PubMed ID: 16648560)
1. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.
Han B; Xie H; Chen Q; Zhang JT
Mol Cancer Ther; 2006 Apr; 5(4):903-12. PubMed ID: 16648560
[TBL] [Abstract][Full Text] [Related]
2. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
3. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3sigma is down-regulated in human prostate cancer.
Urano T; Takahashi S; Suzuki T; Fujimura T; Fujita M; Kumagai J; Horie-Inoue K; Sasano H; Kitamura T; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2004 Jul; 319(3):795-800. PubMed ID: 15184053
[TBL] [Abstract][Full Text] [Related]
5. Cooperative effect of p21Cip1/WAF-1 and 14-3-3sigma on cell cycle arrest and apoptosis induction by p14ARF.
Hemmati PG; Normand G; Gillissen B; Wendt J; Dörken B; Daniel PT
Oncogene; 2008 Dec; 27(53):6707-19. PubMed ID: 18806827
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of the cell type-specific gene 14-3-3sigma.
Oshiro MM; Futscher BW; Lisberg A; Wozniak RJ; Klimecki WT; Domann FE; Cress AE
Neoplasia; 2005 Sep; 7(9):799-808. PubMed ID: 16229802
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition.
Meng S; Arbit T; Veeriah S; Mellinghoff IK; Fang F; Vivanco I; Rohle D; Chan TA
Cell Cycle; 2009 Jul; 8(14):2238-46. PubMed ID: 19502805
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.
Yang H; Zhao R; Lee MH
Mol Cancer Ther; 2006 Feb; 5(2):253-60. PubMed ID: 16505098
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
Lodygin D; Diebold J; Hermeking H
Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
[TBL] [Abstract][Full Text] [Related]
11. 14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation.
Zhang Y; Karas M; Zhao H; Yakar S; LeRoith D
J Biol Chem; 2004 Aug; 279(33):34353-60. PubMed ID: 15187095
[TBL] [Abstract][Full Text] [Related]
12. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
13. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis.
Liu Y; Liu H; Han B; Zhang JT
Cancer Res; 2006 Mar; 66(6):3248-55. PubMed ID: 16540677
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
Schultz J; Ibrahim SM; Vera J; Kunz M
Mol Cancer; 2009 Jul; 8():53. PubMed ID: 19642975
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer.
Radhakrishnan VM; Jensen TJ; Cui H; Futscher BW; Martinez JD
Genes Chromosomes Cancer; 2011 Oct; 50(10):830-6. PubMed ID: 21755566
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.
Mhawech P; Benz A; Cerato C; Greloz V; Assaly M; Desmond JC; Koeffler HP; Lodygin D; Hermeking H; Herrmann F; Schwaller J
Mod Pathol; 2005 Mar; 18(3):340-8. PubMed ID: 15257317
[TBL] [Abstract][Full Text] [Related]
17. Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.
Motokura T; Nakamura Y; Sato H
BMC Cancer; 2007 Nov; 7():217. PubMed ID: 18036248
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3sigma controls mitotic translation to facilitate cytokinesis.
Wilker EW; van Vugt MA; Artim SA; Huang PH; Petersen CP; Reinhardt HC; Feng Y; Sharp PA; Sonenberg N; White FM; Yaffe MB
Nature; 2007 Mar; 446(7133):329-32. PubMed ID: 17361185
[TBL] [Abstract][Full Text] [Related]
19. Loss of 14-3-3sigma in prostate cancer and its precursors.
Cheng L; Pan CX; Zhang JT; Zhang S; Kinch MS; Li L; Baldridge LA; Wade C; Hu Z; Koch MO; Ulbright TM; Eble JN
Clin Cancer Res; 2004 May; 10(9):3064-8. PubMed ID: 15131044
[TBL] [Abstract][Full Text] [Related]
20. Binding of 14-3-3beta but not 14-3-3sigma controls the cytoplasmic localization of CDC25B: binding site preferences of 14-3-3 subtypes and the subcellular localization of CDC25B.
Uchida S; Kuma A; Ohtsubo M; Shimura M; Hirata M; Nakagama H; Matsunaga T; Ishizaka Y; Yamashita K
J Cell Sci; 2004 Jun; 117(Pt 14):3011-20. PubMed ID: 15173315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
